单剂BNT162b2可预防SARS-CoV-2: COVID-19家庭聚集性病例报告

J. A. Morales-Contreras, Jesús Arturo Ruiz-Quiñonez, Alberto Roblero-Hernández, Gibran Horemheb-Rubio, Samuel Suarez Mendez
{"title":"单剂BNT162b2可预防SARS-CoV-2: COVID-19家庭聚集性病例报告","authors":"J. A. Morales-Contreras, Jesús Arturo Ruiz-Quiñonez, Alberto Roblero-Hernández, Gibran Horemheb-Rubio, Samuel Suarez Mendez","doi":"10.32776/revbiomed.v32i3.912","DOIUrl":null,"url":null,"abstract":"Background. Coronavirus 2019 (COVID-19) disease is an infectious disease caused by the virus \"Severe Acute Respiratory Syndrome Coronavirus 2\" (SARS-CoV-2). This virus generated a pandemic in 2020 and has affected millions of people worldwide. Facing the need to prevent its contagion, the vaccine BNT162b2 was approved in December 2020 in Mexico and started administered in healthcare workers. Case presentation. We presented here, two healthcare workers vaccinated with one single dose of BNT162b2, who lives in a family nucleus with high transmission rate of SARS-CoV-2. These healthcare workers, identified in the manuscript as patient E and F, were asymptomatic and their real-time RT-PCR test for SARS-CoV-2 resulted negative, while the rest of the family (patients A-D) were SARS-CoV-2 positive. The antibody titers IgG anti-spike of patient F (after the second dose; 1080 Au/mL) turned out greater than patient E (before the second dose; 37.1 Au/mL). Discussion. To our knowledge this is the first case report of the protective effect of single BNT162b2 vaccine dose in the context of high transmission rates within a family nucleus. Despite changes induced by BNT162b2 in the antibody titers with single or double dose vaccination, a single dose of BNT162b2 showed to be sufficient for immunization of patients against COVID-19.","PeriodicalId":32535,"journal":{"name":"Revista Biomedica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19.\",\"authors\":\"J. A. Morales-Contreras, Jesús Arturo Ruiz-Quiñonez, Alberto Roblero-Hernández, Gibran Horemheb-Rubio, Samuel Suarez Mendez\",\"doi\":\"10.32776/revbiomed.v32i3.912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. Coronavirus 2019 (COVID-19) disease is an infectious disease caused by the virus \\\"Severe Acute Respiratory Syndrome Coronavirus 2\\\" (SARS-CoV-2). This virus generated a pandemic in 2020 and has affected millions of people worldwide. Facing the need to prevent its contagion, the vaccine BNT162b2 was approved in December 2020 in Mexico and started administered in healthcare workers. Case presentation. We presented here, two healthcare workers vaccinated with one single dose of BNT162b2, who lives in a family nucleus with high transmission rate of SARS-CoV-2. These healthcare workers, identified in the manuscript as patient E and F, were asymptomatic and their real-time RT-PCR test for SARS-CoV-2 resulted negative, while the rest of the family (patients A-D) were SARS-CoV-2 positive. The antibody titers IgG anti-spike of patient F (after the second dose; 1080 Au/mL) turned out greater than patient E (before the second dose; 37.1 Au/mL). Discussion. To our knowledge this is the first case report of the protective effect of single BNT162b2 vaccine dose in the context of high transmission rates within a family nucleus. Despite changes induced by BNT162b2 in the antibody titers with single or double dose vaccination, a single dose of BNT162b2 showed to be sufficient for immunization of patients against COVID-19.\",\"PeriodicalId\":32535,\"journal\":{\"name\":\"Revista Biomedica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Biomedica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32776/revbiomed.v32i3.912\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Biomedica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32776/revbiomed.v32i3.912","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景2019冠状病毒(新冠肺炎)病是一种由“严重急性呼吸综合征冠状病毒2”(SARS-CoV-2)引起的传染病。这种病毒在2020年引发了一场大流行病,并影响了全球数百万人。面对预防其传染的需要,BNT162b2疫苗于2020年12月在墨西哥获得批准,并开始在医护人员中接种。案例介绍。我们在这里介绍了两名接种了单剂BNT162b2疫苗的医护人员,他们生活在严重急性呼吸系统综合征冠状病毒2型高传播率的家庭核心。这些医护人员在手稿中被确认为患者E和F,没有症状,他们对严重急性呼吸系统综合征冠状病毒2型的实时RT-PCR检测结果为阴性,而家庭其他成员(患者A-D)则呈严重急性呼吸系统冠状病毒2型阳性。患者F(第二次给药后;1080 Au/mL)的IgG抗刺突抗体滴度大于患者E(第二剂给药前;37.1 Au/mL。讨论据我们所知,这是首次在家庭核心内高传播率的情况下,单剂BNT162b2疫苗具有保护作用的病例报告。尽管单剂或双剂疫苗接种后BNT162b2诱导抗体滴度发生变化,但单剂BNT162b2已足以为患者接种新冠肺炎疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19.
Background. Coronavirus 2019 (COVID-19) disease is an infectious disease caused by the virus "Severe Acute Respiratory Syndrome Coronavirus 2" (SARS-CoV-2). This virus generated a pandemic in 2020 and has affected millions of people worldwide. Facing the need to prevent its contagion, the vaccine BNT162b2 was approved in December 2020 in Mexico and started administered in healthcare workers. Case presentation. We presented here, two healthcare workers vaccinated with one single dose of BNT162b2, who lives in a family nucleus with high transmission rate of SARS-CoV-2. These healthcare workers, identified in the manuscript as patient E and F, were asymptomatic and their real-time RT-PCR test for SARS-CoV-2 resulted negative, while the rest of the family (patients A-D) were SARS-CoV-2 positive. The antibody titers IgG anti-spike of patient F (after the second dose; 1080 Au/mL) turned out greater than patient E (before the second dose; 37.1 Au/mL). Discussion. To our knowledge this is the first case report of the protective effect of single BNT162b2 vaccine dose in the context of high transmission rates within a family nucleus. Despite changes induced by BNT162b2 in the antibody titers with single or double dose vaccination, a single dose of BNT162b2 showed to be sufficient for immunization of patients against COVID-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
19
审稿时长
4 weeks
期刊最新文献
Alexis Carrel: un médico innovador Eutanasia y suicidio medicamente asistido Resistencia a antimicrobianos, la otra cara de la pandemia por SARS-CoV-2 Receptor de los productos finales de glicación avanzada (RAGE) como biomarcador de la obesidad infantil Topical treatment of cutaneous leishmaniasis using a nanoemulsion cream-based on generic pentavalent antimony. Case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1